Have you evaluated the performance of Perrigo's (PRGO) international operations during the quarter that concluded in March 2025? Considering the extensive worldwide presence of this drug company, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investor ...

Perrigo (PRGO) reported adjusted earnings of 60 cents per share in the first quarter of 2025, beating the Zacks Consensus Estimate of 56 cents. The reported figure increased 107% year over year, primarily driven by improved margins and lower variable expenses.Net sales declined 3.5% year over year to $1.04 billion, missing the Zacks Consensus Estimate of $1.08 billion. The downside was due to the loss of sales stemming from exited businesses and product lines, and unfavorable currency movements.During the q ...

Perrigo Company (PRGO) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations & Corporate CommunicationsPatrick Taylor - President & CEOEduardo Bezerra - Executive VP & CFOSarah Whitaker Clemente - Director, HealthcareDaniel Biolsi - Managing Director Conference Call Participants Ethan Brown - Equity Research AnalystSusan Anderson - Managing Director & Senior AnalystKeith Devas - Analyst Operator ladies and gentlemen, and welcome to t ...

Perrigo Company (PRGO) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 ladies and gentlemen, and welcome to the Perrigo Q1 twenty twenty five Financial Results Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Wednesday, 05/07/2025. I would now like to turn the conference over to Brad Joseph, VP, Global Investor Relations. Please go ahead. Speaker1 Good morning and good afternoon ...

Perrigo (PRGO) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.14%. A quarter ago, it was expected that this drug company would post earnings of $0.92 per share when it actually produced earnings of $0.93, delivering a surprise of 1.09%.Over the last four quarters, the company has s ...

Q1 2025 Earnings Presentation May 7, 2025 Bradley Joseph VP Investor Relations & Corporate Communications Forward-Looking Statements Certain statements in this presentation are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or ...

EXHIBIT 99.1 Fiscal Year 2025 Outlook: • The Company widens its fiscal 2025 outlook for reported net sales growth to 0% to 3% from 1% to 3% and organic net sales growth to 1.5% to 4.5% from 2.5% to 4.5%. The Company reaffirms all other 2025 financial targets, including adj. EPS. This outlook includes known impacts from marcroeconomic uncertainty, including tariffs (see "Known Impacts from Macroeconomic Uncertainty" section below for details). (1) See attached Appendix for details. Change in net sales on an ...

Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor DayDelivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC BrandsWidened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS RangeDUBLIN, May 7, 2025 /PRNewswire/ --First Quarter 2025 Highlights: Net sales of $1.04 billion declined ...

公司业绩预期 - 预计Perrigo Company plc (PRGO)将在2025年第一季度财报中超出预期 财报公布时间为5月7日开盘前 [1] - 上一季度公司盈利超出预期1.09% [1] - Zacks对销售额和每股收益的一致预期分别为10.8亿美元和53美分 [1] 业务部门表现 - 公司业务分为两个部门：Consumer Self Care Americas (CSCA)和Consumer Self Care International (CSCI) [1] - CSCA部门销售额的Zacks一致预期和模型预期分别为6.57亿美元和6.38亿美元 [2] - CSCI部门销售额的Zacks一致预期和模型预期分别为4.32亿美元和4.34亿美元 [2] 历史业绩表现 - 过去四个季度中 公司盈利三次超出预期 一次未达预期 平均超出幅度为7.78% [4] - 公司股价年内表现逊于行业平均水平 [4] 模型预测 - 公司当前具有+2.37%的Earnings ESP和Zacks Rank 3评级 符合盈利超预期的模型条件 [6][7] 其他生物科技公司 - CytomX Therapeutics (CTMX)具有+38.89%的Earnings ESP和Zacks Rank 1评级 年内股价下跌22% 过去四个季度平均盈利超出幅度达180.70% [8] - argenx (ARGX)具有+10.92%的Earnings ESP和Zacks Rank 3评级 年内股价上涨6% 过去四个季度平均盈利超出幅度达345.11% 将于5月8日公布财报 [9] - Novavax (NVAX)具有+495.75%的Earnings ESP和Zacks Rank 3评级 年内股价下跌20% 过去四个季度平均盈利未达预期0.48% 将于5月8日公布财报 [9][10]

并购事件 - 2015年迈兰公司(Mylan)对Perrigo(NYSE PRGO)发起主动收购要约 初始报价为290亿美元 [1] - 后续将收购报价提高至340亿美元 但遭到Perrigo时任CEO Joseph Papa拒绝 [1] 投资服务平台 - 提供安卓应用和网站工具 包含可输入任意股票代码获取精选研究资料的开发中软件 [3] - 为需要实操支持的投资者提供专家服务 包括筛选优质股票及制定买卖策略 [3] - 平台提供免费试用 用户可申请使用工具体验服务 [3]